# Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

> **NCT00753688** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 369 (actual)

## Conditions studied

- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** PAZOPANIB
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00753688
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-11
- **Final completion:** 2012-12
- **Target enrollment:** 369 (ACTUAL)
- **Last updated:** 2013-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00753688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00753688, "Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00753688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*